Treatment of Pulmonary Disease Due to Mycobacterium kansasii: Recent Experience with Rifampin
Records of 244 patients with Mycobacterium kansasii isolated from their sputum were reviewed. Of the 244 patients, 82 failed to meet study criteria and were excluded. Response to treatment and posttreatment follow-up was evaluated in 162 patients. Overall, 135 patients (83%) achieved negative sputum...
Saved in:
Published in: | Reviews of infectious diseases Vol. 3; no. 5; pp. 1035 - 1039 |
---|---|
Main Authors: | , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
University of Chicago Press
01-09-1981
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Records of 244 patients with Mycobacterium kansasii isolated from their sputum were reviewed. Of the 244 patients, 82 failed to meet study criteria and were excluded. Response to treatment and posttreatment follow-up was evaluated in 162 patients. Overall, 135 patients (83%) achieved negative sputum cultures within six months. Among 32 patients whose drug regimen included rifampin, all 32 (100%) had negative cultures at the fourth and fifth months, but two relapsed during the sixth month, with cultures resistant to 1.0 and 25 μg of rifampin/ml. Among 130 patients whose regimen did not include rifampin, negative sputum cultures were achieved by the sixth month in 101 (80%). In these patients, no significant influence could be attributed to (1) the use of three-drug vs. two-drug regimens; (2) the in vitro susceptibility of pretreatment cultures to isoniazid; (3) the coexistence of obstructive airway disease; or (4) the early use of pulmonary resection. The susceptibility of pretreatment cultures to streptomycin in those who received this drug may have influenced outcome. The late follow-up showed a cumulative relapse rate of 13% over five years in those who had achieved negative cultures initially, and the relapse rate did not appear to be influenced by pulmonary resection as part of the treatment. |
---|---|
AbstractList | Records of 244 patients with Mycobacterium kansasii isolated from their sputum were reviewed. Of the 244 patients, 82 failed to meet study criteria and were excluded. Response to treatment and posttreatment follow-up was evaluated in 162 patients. Overall, 135 patients (83%) achieved negative sputum cultures within six months. Among 32 patients whose drug regimen included rifampin, all 32 (100%) had negative cultures at the fourth and fifth months, but two relapsed during the sixth month, with cultures resistant to 1.0 and 25 μg of rifampin/ml. Among 130 patients whose regimen did not include rifampin, negative sputum cultures were achieved by the sixth month in 101 (80%). In these patients, no significant influence could be attributed to (1) the use of three-drug vs. two-drug regimens; (2) the in vitro susceptibility of pretreatment cultures to isoniazid; (3) the coexistence of obstructive airway disease; or (4) the early use of pulmonary resection. The susceptibility of pretreatment cultures to streptomycin in those who received this drug may have influenced outcome. The late follow-up showed a cumulative relapse rate of 13% over five years in those who had achieved negative cultures initially, and the relapse rate did not appear to be influenced by pulmonary resection as part of the treatment. Records of 244 patients with M. kansasii isolated from their sputum were reviewed. Overall, 135 patients achieved negative sputum cultures within six months. Among 32 patients whose drug regimen included rifampin, all 32 had negative cultures at the fourth and fifth months, but two relapsed during the sixth month, with cultures resistant to 1.0 and 25 mu g of rifampin/ml. Among 130 patients whose regimen did not include rifampin, negative sputum cultures were achieved by the sixth month in 101 (80%). In these patients, no significant influence could be attributed to (1) the use of three-drug vs. two-drug regimens; (2) the in vitro susceptibility of pretreatment cultures to isoniazid; (3) the coexistence of obstructive airway disease; or (4) the early use of pulmonary resection. Records of 244 patients with Mycobacterium kansasii isolated from their sputum were reviewed. Of the 244 patients, 82 failed to meet study criteria and were excluded. Response to treatment and posttreatment follow-up was evaluated in 162 patients. Overall, 135 patients (83%) achieved negative sputum cultures within six months. Among 32 patients whose drug regimen included rifampin, all 32 (100%) had negative cultures at the fourth and fifth months, but two relapsed during the sixth month, with cultures resistant to 1.0 and 25 micrograms of rifampin/ml. Among 130 patients whose regimen did not include rifampin, negative sputum cultures were achieved by the sixth month in 101 (80%). In these patients, no significant influence could be attributed to (1) the use of three-drug vs. two-drug regimens; (2) the in vitro susceptibility of pretreatment cultures to isoniazid; (3) the coexistence of obstructive airway disease; or (4) the early use of pulmonary resection. The susceptibility of pretreatment cultures to streptomycin in those who received this drug may have influenced outcome. The late follow-up showed a cumulative relapse rate of 13% over five years in those who had achieved negative cultures initially, and the relapse rate did not appear to be influenced by pulmonary resection as part of the treatment. |
Author | Julian Silverblatt James W. Raleigh Margaret C. Bailey Willy Pezzia Elizabeth A. Toth |
Author_xml | – sequence: 1 givenname: W surname: Pezzia fullname: Pezzia, W – sequence: 2 givenname: J W surname: Raleigh fullname: Raleigh, J W – sequence: 3 givenname: M C surname: Bailey fullname: Bailey, M C – sequence: 4 givenname: E A surname: Toth fullname: Toth, E A – sequence: 5 givenname: J surname: Silverblatt fullname: Silverblatt, J |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/7339801$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkDtPwzAYRT0UlVL4ByB5YovkxI84bKgtD6kIVJURRY79RbgkdogdQf89Qa1Yme5wzr3DPUMT5x1M0IykIkuIlOIUnYWwI4TTnIkpmuaUFpKkM_S27UHFFlzEvsYvQ9N6p_o9XtoAKgBeDoCjx0977SulI_R2aPGHckEFa2_wBvRvdfXdjQScBvxl4zve2Fq1nXXn6KRWTYCLY87R691qu3hI1s_3j4vbdbLLuIyJ5IRDRljGjFIVMVzmVU0LnfKCcJaq2phK5FwLDaQwecGNqE0uCqkoYbXQdI6uD7td7z8HCLFsbdDQNMqBH0KZUym5IPJfMeWMMML5KF4dxaFqwZRdb9vxl_J43MgvD3wXou__MGM8E0zSH2ZodFM |
ContentType | Journal Article |
Copyright | Copyright 1981 The University of Chicago |
Copyright_xml | – notice: Copyright 1981 The University of Chicago |
DBID | CGR CUY CVF ECM EIF NPM 7QL C1K 7X8 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Bacteriology Abstracts (Microbiology B) MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EndPage | 1039 |
ExternalDocumentID | 7339801 4452648 |
Genre | Journal Article |
GroupedDBID | .GJ 2AX 3O- 5RE 6.Y AACGO AAMVS AANCE AAPGJ AAQQT AAWDT ABBHK ABPLY ABSAR ABSMQ ABTLG ABXSQ ACFRR ACGFS ACPQN ACUTJ ADZLD AEKPW AEUPB AEXZC AFFNX AFYAG AGKRT ALMA_UNASSIGNED_HOLDINGS AQDSO AQKUS AQVQM AZFZN BZKNY DCCCD DNJUQ DOOOF DWIUU EIHJH F5P HQ3 HTVGU J5H JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JSODD JST L7B MBLQV OBFPC PB- QBD ROZ SA0 TMA ZGI 53G ACMRT ACZBC ADACV AFSHK AGMDO AVNTJ CGR CUY CVF ECM EIF IPSME NPM UAP 7QL C1K 7X8 |
ID | FETCH-LOGICAL-j258t-8505e20424daab0d587bf39c1590541afddb675c6ce09d795d6fd7698a304f6c3 |
IEDL.DBID | JSG |
ISSN | 0162-0886 |
IngestDate | Fri Oct 25 01:29:51 EDT 2024 Tue Aug 27 04:32:53 EDT 2024 Sat Sep 28 08:36:32 EDT 2024 Fri Feb 02 07:03:09 EST 2024 |
IsPeerReviewed | false |
IsScholarly | false |
Issue | 5 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-j258t-8505e20424daab0d587bf39c1590541afddb675c6ce09d795d6fd7698a304f6c3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-2 ObjectType-Feature-1 content type line 23 SourceType-Conference Papers & Proceedings-1 ObjectType-Conference-3 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 |
PMID | 7339801 |
PQID | 15404055 |
PQPubID | 23462 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_73885608 proquest_miscellaneous_15404055 pubmed_primary_7339801 jstor_primary_4452648 |
PublicationCentury | 1900 |
PublicationDate | 1981 Sep-Oct |
PublicationDateYYYYMMDD | 1981-09-01 |
PublicationDate_xml | – month: 09 year: 1981 text: 1981 Sep-Oct |
PublicationDecade | 1980 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Reviews of infectious diseases |
PublicationTitleAlternate | Rev Infect Dis |
PublicationYear | 1981 |
Publisher | University of Chicago Press |
Publisher_xml | – name: University of Chicago Press |
SSID | ssj0053746 |
Score | 1.2237619 |
Snippet | Records of 244 patients with Mycobacterium kansasii isolated from their sputum were reviewed. Of the 244 patients, 82 failed to meet study criteria and were... Records of 244 patients with M. kansasii isolated from their sputum were reviewed. Overall, 135 patients achieved negative sputum cultures within six months.... |
SourceID | proquest pubmed jstor |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1035 |
SubjectTerms | Adult Aged Antibacterials Follow-Up Studies Fungal infections Fungal lung diseases Humans Isoniazid - pharmacology Lung diseases Male Microbial Sensitivity Tests Middle Aged Mycobacterium Infections, Nontuberculous - drug therapy Mycobacterium kansasii Nontuberculous Mycobacteria - drug effects Obstructive lung diseases Pretreatment Pulmonary tuberculosis Relapse Rifampin - therapeutic use Session VI: Clinical Aspects Sputum Sputum - microbiology Streptomycin - pharmacology Tuberculosis, Pulmonary - drug therapy Tuberculosis, Pulmonary - surgery |
Title | Treatment of Pulmonary Disease Due to Mycobacterium kansasii: Recent Experience with Rifampin |
URI | https://www.jstor.org/stable/4452648 https://www.ncbi.nlm.nih.gov/pubmed/7339801 https://search.proquest.com/docview/15404055 https://search.proquest.com/docview/73885608 |
Volume | 3 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1NT8IwGG6Eg_HiJ0T8wB64LrJ1XVtvRkBjgjGCiRdD2rVNUNgIsAP_3rcd0xOJ97VN3o_2WZ-n74tQhxlKjSQ6sILQIBbEBlJ248BoHSlhJRHaX12M2MsH7_VdmZxO9RbGySq9LtCz-ACQ1Mzcxq4PdsxrqMZ98j2PHqvdlhJWPsYJkyiAjEkqXeFuxOhPjsHR_9Y8RodbZIjvS1eeoD2TnaL94Zb7PkOf40oTjnOLX4sZBJBcbnCvpFhwrzB4nePhJoUU9SWYizn-dt3AV9PpHQZ86Ib-lTbG7goWv02tnC-mWQO9D_rjh6dg2xwh-IooXwccoIuJHHGppVRdTTlTlogU4AmgsFBarRX8DKRJarpCM0F1YjVLBJekG9skJU1Uz_LMnCOsAIVx5zMd6lgpKiOeWs6siQCOSZW2UMObZ7IoC2BMtrZpoZvKxBMISsc0yMzkxWoCuAw2B0p3f8EI5wC2YI5m6ZvfyRkhAo7Nix2LXqKDUPCwlHldofp6WZhrVFvpou31nG0fHj-9G7r7 |
link.rule.ids | 315,782,786,808,811,58025,58037,58258,58270 |
linkProvider | JSTOR |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjZ3PS8MwFMeDm6Be_C3OX8vBa7FtmibxJs4xcRuiE7xISZoEqq4b23rYf-9Lu-pp4L1J4L38-DTvm_cQumaGUiOJ9qwg1IsEsZ6UfuQZrUMlrCRCl1cXr2z4zjsPLk3Odf0WxskqS11gGcUHQFLf5iZydbAj3kCblPuEVcK9er-lhFXPcYI49GDNxLWycD0zlmdHd-9_o-6j3RUb4rvKmQdow-SHaGuwin4foY9RrQrHE4ufi2-YQnK2xJ0qyII7hcGLCR4sU1ikZRLmYoy_XD3weZbdYiBE1_QvuTF2l7D4JbNyPM3yY_TWfRjd97xVeQTvM6R84XGAFxO60KWWUvmacqYsESkACnBYIK3WCn4H0jg1vtBMUB1bzWLBJfEjG6fkBDXzSW5OEVbAYdx5TQc6UorKkKeWM2tCADKp0hY6Ls2TTKsUGMnKNi3Urk2cwLR0sQaZm0kxT4DMYHugdP0XjHAOuAV9nFS--e2cESLg4DxbM2gbbfdGg37Sfxw-naOdQPCgEn1doOZiVphL1Jjr4qqcJD9mXb1U |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjZ1LTwIxEIAbwYR48YkRX_TgwcsGdrvdtt6MQDQKIYqJF7Npt22CwkKAPfDvne6yeiLx3kcyM22_dqYzCN0wQ6mRRHtWEOqFglhPynboGa0DJawkQudPF29s8ME7XZcm57b8C-PCKvO4wNyLD4CkJqY117YVulrYIa-gXQqXGl7UBij3XEpY8SXHjwIP1k1URhdu58b8_Ogd_H_mQ7S_YUR8Xyj1CO2Y9BjV-hsv-An6HJXR4Xhm8TCbgCnJxRp3CmcL7mQGr2a4v05gsebJmLMp_nZ1wZfj8R0GUnRd_5IcY_cYi1_HVk7n47SO3nvd0cOjtymT4H2BIFYeB4gxgXNhailVW1POlCUiAVABHvOl1VrBtSCJEtMWmgmqI6tZJLgk7dBGCTlF1XSWmjOEFfAYd9rTvg6VojLgieXMmgDATKqkgeq5iOJ5kQoj3simgZqlmGMwT-dzkKmZZcsYCA22CUq3t2CEc8AuGOO00M_v4IwQAQfo-ZZJm6g27PTil6fB8wXa8wX3i9ivS1RdLTJzhSpLnV3ndvIDkkq_zQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+of+Pulmonary+Disease+Due+to+Mycobacterium+kansasii%3A+Recent+Experience+with+Rifampin&rft.jtitle=Reviews+of+infectious+diseases&rft.au=Willy+Pezzia&rft.au=James+W.+Raleigh&rft.au=Margaret+C.+Bailey&rft.au=Elizabeth+A.+Toth&rft.date=1981-09-01&rft.pub=University+of+Chicago+Press&rft.issn=0162-0886&rft.volume=3&rft.issue=5&rft.spage=1035&rft.epage=1039&rft.externalDocID=4452648 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0162-0886&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0162-0886&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0162-0886&client=summon |